GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 49-60 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.

Salim H; Qureshi S; Gulsin GS; Khan HR; Waqas SA; McCann GP; Garg A; Shurrab M; Khunti K; Rashid M

2026PubMedDirectly related

The Role and Mechanism of Incretins in Gynaecologic Diseases.

Yan J; Cao M; Ding Y; Zhang Y; Sun Y; Jiang G; Zhang Y; Kang L; Zhou X; Luo J; Li B

Jan 1, 2026Endocrinology, diabetes & metabolism

2026PubMedDirectly related

New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.

Panou T; Gouveri E; Popovic DS; Papanas N

Jan 1, 2026Diabetes therapy : research, treatment and education of diabetes and related disorders

2026PubMedDirectly related

Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.

Mera-Carreiro S; Ramos-Leví A; Matía-Martín P; Bernaldo-Madrid B; Rodríguez-Carrillo C; Marcuello-Foncillas C; Pérez-Ferre N; Torres-García A; Sánchez-Pernaute A; Esteban-López-Jamar JM; Rubio-Herrera MÁ

Jan 1, 2026Obesity surgery

2026PubMedDirectly related

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)

Jan 1, 2026Journal of hepatology

2026PubMedDirectly related

Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.

Cautela D; Incarbona V; Lombardi A; Laratta B; Castaldo CM; Balestrieri ML; Mocini E; Migliaccio S; Tardito D

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.

Myśliwczyk D; Myśliwiec M; Minarowska A; Wasilewska E

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.

Kaltsas A; Gkioxaris V; Giannakas T; Zachariou A; Dimitriadis F; Sofikitis N; Chrisofos M

Jan 1, 2026Journal of clinical medicine

2026PubMedDirectly related

Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.

Enache V; Popescu DC; Marcu B; Diaconu M; Nechita AC

Jan 1, 2026Medicina (Kaunas, Lithuania)

2026PubMedDirectly related

Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.

Roach KA; Khazaee M; Mohar I; Boon D; Cronin B; Gauthier AG

Jan 1, 2026Regulatory toxicology and pharmacology : RTP

2026PubMedDirectly related

Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.

Lin CL; Lin KC; Yu JM; Chang CL; Lin YY; Fang CY; Chen WM; Wu SY

Jan 1, 2026Nature communications

2026PubMedDirectly related

Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.

Brogaard E; Nielsen VW; Pedersen NH; Thomsen SF

Jan 1, 2026Expert opinion on therapeutic targets